The microbiome business of GI Innovation and Mediogen is to be actualized this year. Their joint venture, GI Biome, aims to become a global player by actively promoting new drug development and bioinformatics businesses from this year onwards, with a strategic plan for long-term growth to reach a market value in the trillion-won range. 

According to GI Biome on the 13th, the anticancer drug 'GB-X01' being developed for colorectal cancer is preparing for Phase 1 clinical trial initiation. Kim Young-seok, CEO of GI Biome, stated, "Our microbiome therapy development will be accelerated this year," and added, "We plan to apply for IND of GB-X01 to MFDS in September." 

Original article: https://n.news.naver.com/mnews/article/018/0005214714?sid=101